200 related articles for article (PubMed ID: 37552290)
1. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial.
Gournay LR; Ferretti ML; Bilsky S; Vance E; Nguyen AM; Mann E; Williams P; Leen-Feldner EW
Psychopharmacology (Berl); 2023 Oct; 240(10):2147-2161. PubMed ID: 37552290
[TBL] [Abstract][Full Text] [Related]
2. A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students.
Stanley TB; Ferretti ML; Bonn-Miller MO; Irons JG
Cannabis Cannabinoid Res; 2023 Dec; 8(6):1090-1099. PubMed ID: 35861792
[No Abstract] [Full Text] [Related]
3. Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial.
Mongeau-Pérusse V; Rizkallah E; Morissette F; Brissette S; Bruneau J; Dubreucq S; Gazil G; Trépanier A; Jutras-Aswad D
J Addict Med; 2022 Sep-Oct 01; 16(5):521-526. PubMed ID: 35135986
[TBL] [Abstract][Full Text] [Related]
4. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.
Bloomfield MAP; Yamamori Y; Hindocha C; Jones APM; Yim JLL; Walker HR; Statton B; Wall MB; Lees RH; Howes OD; Curran VH; Roiser JP; Freeman TP
Psychopharmacology (Berl); 2022 May; 239(5):1539-1549. PubMed ID: 35445839
[TBL] [Abstract][Full Text] [Related]
5. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.
Gundugurti PR; Banda N; Yadlapalli SSR; Narala A; Thatikonda R; Kocherlakota C; Kothapalli KS
Asian J Psychiatr; 2024 Jul; 97():104073. PubMed ID: 38797087
[TBL] [Abstract][Full Text] [Related]
8. Practical considerations for testing the effects of cannabidiol on human anxiety.
Leen-Feldner EW; Bynion TM; Gournay R; Bonn-Miller MO; Feldner MT
J Anxiety Disord; 2021 Aug; 82():102429. PubMed ID: 34058457
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol as a Potential Treatment for Anxiety Disorders.
Blessing EM; Steenkamp MM; Manzanares J; Marmar CR
Neurotherapeutics; 2015 Oct; 12(4):825-36. PubMed ID: 26341731
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.
Hurd YL; Spriggs S; Alishayev J; Winkel G; Gurgov K; Kudrich C; Oprescu AM; Salsitz E
Am J Psychiatry; 2019 Nov; 176(11):911-922. PubMed ID: 31109198
[TBL] [Abstract][Full Text] [Related]
11. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study.
Spinella TC; Stewart SH; Naugler J; Yakovenko I; Barrett SP
Psychopharmacology (Berl); 2021 Jul; 238(7):1965-1977. PubMed ID: 33813611
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Bergamaschi MM; Queiroz RH; Chagas MH; de Oliveira DC; De Martinis BS; Kapczinski F; Quevedo J; Roesler R; Schröder N; Nardi AE; Martín-Santos R; Hallak JE; Zuardi AW; Crippa JA
Neuropsychopharmacology; 2011 May; 36(6):1219-26. PubMed ID: 21307846
[TBL] [Abstract][Full Text] [Related]
13. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
de Faria SM; de Morais Fabrício D; Tumas V; Castro PC; Ponti MA; Hallak JE; Zuardi AW; Crippa JAS; Chagas MHN
J Psychopharmacol; 2020 Feb; 34(2):189-196. PubMed ID: 31909680
[TBL] [Abstract][Full Text] [Related]
14. Effect of prior foot shock stress and Δ
Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
[TBL] [Abstract][Full Text] [Related]
15. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Crippa JA; Derenusson GN; Ferrari TB; Wichert-Ana L; Duran FL; Martin-Santos R; Simões MV; Bhattacharyya S; Fusar-Poli P; Atakan Z; Santos Filho A; Freitas-Ferrari MC; McGuire PK; Zuardi AW; Busatto GF; Hallak JE
J Psychopharmacol; 2011 Jan; 25(1):121-30. PubMed ID: 20829306
[TBL] [Abstract][Full Text] [Related]
16. Effects of cannabidiol (CBD) on regional cerebral blood flow.
Crippa JA; Zuardi AW; Garrido GE; Wichert-Ana L; Guarnieri R; Ferrari L; Azevedo-Marques PM; Hallak JE; McGuire PK; Filho Busatto G
Neuropsychopharmacology; 2004 Feb; 29(2):417-26. PubMed ID: 14583744
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
Melas PA; Scherma M; Fratta W; Cifani C; Fadda P
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668469
[TBL] [Abstract][Full Text] [Related]
18. Protocol for a pragmatic trial of Cannabidiol (CBD) to improve chronic pain symptoms among United States Veterans.
Bergmans RS; Wegryn-Jones R; Klida C; Kurtz V; Thomas L; Williams DA; Clauw DJ; Kidwell KM; Bohnert ASB; Boehnke KF
BMC Complement Med Ther; 2024 Jun; 24(1):250. PubMed ID: 38951902
[TBL] [Abstract][Full Text] [Related]
19. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
20. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze.
Fabris D; Carvalho MC; Brandão ML; Prado WA; Zuardi AW; Crippa JA; de Oliveira AR; Lovick TA; Genaro K
J Psychopharmacol; 2022 Dec; 36(12):1371-1383. PubMed ID: 36239039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
